-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

702.O2.6 702. CAR-T Cell Therapies: Basic and Translational: Acute and Late Toxicities Following CAR-T Cell Therapy

Symposia: CAR-T Cell Therapies: Basic and Translational Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, Combination therapy, Apoptosis, Translational Research, CLL, Lymphomas, Non-Hodgkin lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, Genomics, T Cell lymphoma, Diseases, Immune mechanism, Indolent lymphoma, Treatment Considerations, Biological therapies, Immunology, Aggressive lymphoma, Lymphoid Malignancies, Adverse Events, Biological Processes, Technology and Procedures, Omics technologies
Monday, December 9, 2024: 2:45 PM-4:15 PM
Room 6CF (San Diego Convention Center)
Moderators:
Karlo Perica, MD, PhD, and Maksim Mamonkin, PhD, Center For Cell and Gene Therapy
Disclosures:
Mamonkin: March Bio: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Other: Leadership, Patents & Royalties: Licensing, Research Funding; NKILT Therapeutics: Membership on an entity's Board of Directors or advisory committees; Fate Therapeutics: Honoraria, Other: Travel, Patents & Royalties: Licensing, Research Funding; Allogene Therapeutics: Patents & Royalties: Licensing; Beam Therapeutics: Patents & Royalties; Amgen: Consultancy, Honoraria, Other: Travel; Galapagos NV: Consultancy, Honoraria, Other: Travel; Laverock Therapeutics: Consultancy.
The majority of the abstracts in this session will highlight acute and late toxicities that may occur after CAR T cell therapy.
2:45 PM

Wannakorn Khopanlert, MD1,2,3*, Truc Huynh2,3*, Brooke L. Kimball2,3*, Grace E. DeFranco2,3,4*, Sophia Y. Goldberg2,3,4*, Dominic A. Skeele2,3,4*, Jennifer M. Feigin2,3,4,5, James H. Girsch, BS2,3,4,6, Olivia L. Sirpilla, BS2,3,4,7, Carli M. Stewart, BS2,3,4,7, Kun Yun, BS, MSc2,3,4,6, Claudia Manriquez Roman, PhD2,3*, Ismail Can, PhD2,3, Omar Gutierrez Ruiz, PhD2,3*, Ekene Ogbodo, PhD2,3*, Long K. Mai2,3*, Hong Xia, MD2,3*, Mehrdad Hefazi, MD2,3, Lionel Aurelien Kankeu Fonkoua, MD2,3*, Michael W. Ruff, MD3,8*, Elizabeth L. Siegler, PhD2,3, Saad S. Kenderian, MD2,3,6,9 and R. Leo Sakemura, MD, PhD2,3,9

1Prince of Songkla University, Hat Yai, Thailand
2Division of Hematology, Mayo Clinic, Rochester, MN
3T Cell Engineering, Mayo Clinic, Rochester, MN
4Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN
5Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN
6Department of Molecular Medicine, Mayo Clinic, Rochester, MN
7Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN
8Department of Neurology, Mayo Clinic, Rochester, MN
9Department of Immunology, Mayo Clinic, Rochester, MN

3:00 PM

Kun Yun, BS, MSc1,2,3, R. Leo Sakemura, MD, PhD1,4, Ismail Can, PhD1, Omar Gutierrez Ruiz, PhD1,4*, Ekene Ogbodo, PhD1,4*, Shuwen Zhang, PhD5*, Truc Huynh1,4*, Claudia Manriquez Roman, PhD1,4*, Olivia L. Sirpilla, BS1,3,4,6, Carli M. Stewart, BS1,3,4,6, James H. Girsch, BS1,2,3,4, Jennifer M. Feigin1,3,4,7, Long K. Mai1,4*, Hong Xia, MD1,4*, Brooke L. Kimball1,4*, Lionel A Kankeu Fonkoua, MD8,9*, Mehrdad Hefazi, MD1,4, Michael W. Ruff, MD1,10*, Fariborz Rakhshan Rohakhtar11*, Vernadette Simon11*, Elizabeth L. Siegler, PhD1,4, Mike Mattie, PhD12*, Sao-Mai Nguyen-Mau13*, Simone Filosto, PhD14* and Saad S. Kenderian, MD1,2,4,15,16

1T Cell Engineering, Mayo Clinic, Rochester, MN
2Department of Molecular Medicine, Mayo Clinic, Rochester, MN
3Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN
4Division of Hematology, Mayo Clinic, Rochester, MN
5Department of Quantitative Health Services, Mayo Clinic, Rochester
6Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN
7Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN
8Department of Oncology, Mayo Clinic, Rochester
9T Cell Engineering, Mayo Clinic, Rochester
10Department of Neurology, Mayo Clinic, Rochester, MN
11Genome Analysis Core, Mayo Clinic, Rochester
12Kite Pharma, a Gilead company, Santa Monica, CA
13Kite Pharma, a Gilead company, Santa Monica
14Kite, a Gilead Company, Santa Monica, CA
15T Cell Engineering, Division of Hematology, Department of Molecular Medicine and Department of Immunology, Mayo Clinic, Rochester, MN
16Department of Immunology, Mayo Clinic, Rochester, MN

3:15 PM

Benjamin F. Frost1,2,3*, Olga Shestova, PhD2,4*, Sara Sleiman, MD2,3*, Brandon Simone, PhD2,3*, Feng Shen, PhD2,3*, Miroslaw Kozlowski, PhD2,4*, Michelle Wang, PharmD, PhD2,3*, J. Joseph Melenhorst, PhD2,3,5, Noelle Frey, MD, MS2,6, Elizabeth O. Hexner, MD, MSTR2,7, Megan M. Davis, PhD2,3*, Joseph A. Fraietta, PhD2,4*, Avery Gaymon, MS2,3*, Rong Xu, PhD2,3*, Chia Sharpe, PhD8, John C. Byrd, MD8, Mark O'Hara, MD2,7*, Adam D. Cohen, MD2,7,9, Stephen J. Schuster, MD2,7,9, Donald L. Seigel2,3,7,10*, Carl H. June, MD2,3,7,10, David L. Porter, MD2,3,7,9 and Saar Gill, MD, PhD2,4,6

1Department of Medicine, Brigham and Women's Hospital, Boston, MA
2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
3Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA
4Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
5Center for Immunotherapy and Precision Immuno-Oncology, Cell Therapy & Immuno-Engineering Program, Lerner Research Institute, Cleveland Clinic, Cleveland, OH
6University of Pennsylvania, Philadelphia, PA
7Abramson Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA
8Department of Internal Medicine, University of Cincinnati, Cincinnati, OH
9Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
10Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

3:30 PM

Jackson Weir1,2*, Katie Maurer, MD, PhD2,3,4, Adi Nagler, PhD3,4*, Hariharan Bharadwaj5*, Jacob Shapiro6*, Somkene Alakwe7*, Vipin Kumar, PhD7*, Brianna Waller, MD8*, Mikaela M. McDonough9*, Jamie Dela Cruz10*, Loida Luna11*, Emma Lin4*, Linsey Gong7*, Qiyu Gong7*, Mehdi Borji, MS2*, Phillip Michaels, MD12, Geraldine Pinkus, MD13*, Catherine J. Wu, MD3,4,14*, Fei Chen, PhD15,16* and Caron A. Jacobson, MD, MMSc4,9

1Biological and Biomedical Sciences Program, Harvard University, Cambridge, MA
2Broad Institute of MIT and Harvard, Cambridge, MA
3Harvard Medical School, Boston, MA
4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
5Department of Pathology, Brigham and Women’s Hospital, Boston, MA
6Biophysics Program, Harvard University, Cambridge
7Broad Institute, Cambridge
8Department of Pathology, Brigham and Women’s Hospital, Cambridge
9Dana-Farber Cancer Institute, Boston, MA
10Dana Farber Cancer Institute, Boston, MA
11Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
12Translational Biomarkers Core, Brigham and Women's Hospital, Boston, MA
13Department of Pathology, Brigham and Women's Hospital, Boston, MA
14Brigham and Women's Hospital, Boston, MA
15Broad Institute of MIT, Boston, MA
16Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA

3:45 PM

Anne Marijn Kramer, MD, PhD1,2,3, Tara Murty, PhD4,5*, Yiyun Chen, PhD6*, Hrishikesh Srinagesh, MD, MSCR7*, Mark P. Hamilton, MD, PhD8,9, Kelvin C. Mo, BA6*, Snehit Prabhu, PhD6*, Moksha Desai, MS6*, Adam Kuo, MS2*, Zachary Ehlinger, MS6*, Warren D. Reynolds, BS6*, John H. Baird, MD10, Yi-Jiun Su, MD7,11*, Neha Agarwal, MS2,7*, Bita Sahaf12,13*, Lori Muffly, MD6,14, Crystal L. Mackall, MD6, David B. Miklos, MD, PhD8,15, Matthew J. Frank12,16,17 and Zinaida Good, PhD6,17

1Cancer Center Amsterdam, Department of Hematology, Amsterdam UMC, Amsterdam, Netherlands
2Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA
3Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Menlo Park, CA
4Stanford University School of Medicine, Palo Alto, CA
5Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Palo Alto, CA
6Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA
7Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA
8Stanford Cancer Institute, Center for Cancer Cell Therapy, Stanford University, Stanford, CA
9Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA
10Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
11Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan
12Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA
13Cancer Correlative Science Unit, Stanford University, Palo Alto, CA
14Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA
15Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA
16Stanford Cancer Institute, Center for Cancer Cell Therapy, Stanford University School of Medicine, Stanford, CA
17These authors contributed equally, Palo Alto, CA

4:00 PM

Kai Rejeski, MD1,2, Teng Fei, PhD3*, Alejandro Luna, MD, PhD1*, Mohammad Alhomoud, MD1, Yannis K. Valtis, MD4, Noriko Nishimura, MD5, Marina Gomez-Llobell, MD1*, Noa Golan Accav6*, Ofrat Beyar-Katz, MD, PhD7*, Sandeep S. Raj, MD1, Magdalena Corona, MD, PhD1*, Alfredo Rivas-Delgado, MD, PhD4, Hamza Sloan Hashmi, MD5*, Sridevi Rajeeve, MD5, Efrat Luttwak, MD8, Michael Scordo, MD9, Gunjan L. Shah, MD10, Maria Lia Palomba, MD8, Michael von Bergwelt-Baildon, MD, PhD11*, Marion Subklewe, MD12, Abraham Avigdor, MD6, Ronit Marcus, MD13*, Avichai Shimoni, MD6*, Arnon Nagler, MD6, Tsila Zuckerman, MD14, Jabour Halloun, MD15*, Uri Greenbaum, MD16, Sham Mailankody, MD, MBBS5, Saad Z. Usmani, MD5, Gilles Salles, MD, PhD17, Jae H. Park, MD18, Miguel Angel Perales, MD4 and Roni Shouval, MD, PhD1

1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
2Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany
3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
4Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
5Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
6Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Aviv, Israel
7Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus; The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel
8Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
9Transplant and Cellular Therapy Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY
10Transplant and Cellular Therapy Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
11Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
12Department of Medicine III, LMU University Hospital, Munich, Germany
13Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical Center, Ramat Gan, Israel
14Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Moshav Ein Ayalla, Israel
15Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel
16Department of Hematology, Soroka University Medical Center, Beer Sheva, Israel
17Lymphoma Service Chief, Memorial Sloan Kettering Cancer Center, New York, NY
18Cell Therapy Service and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

*signifies non-member of ASH